* InspireMD Inc NSPR.OQ NSPR.O is expected to show a
rise in
quarterly revenue when it reports results on March 8.
* The Tel Aviv-yafo Israel-based company is expected to
report
a 722.8% increase in revenue to $1.3 million from $158 thousand
a year ago, according to the estimate from one analyst, based on
Refinitiv data.
* Refinitiv's mean analyst estimate for InspireMD Inc is
for a
loss of 78 cents per share. For the same quarter last year, the
company reported a loss of $1.20 per share.
* The one available analyst rating on the shares is "buy".
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for InspireMD
Inc is
$9, about 71% above its last closing price of $2.61.
This summary was machine generated March 4 at 14:03 GMT. All
figures in US dollars unless otherwise stated